<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240606180819
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240606180819" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 06 Jun 2024 22:08:21 +0000</lastbuilddate>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Risk prediction by ambulatory blood pressure monitoring in non-diabetic and diabetic patients: better than office measurements</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842583/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae171. doi: 10.1093/eurheartj/ehae171. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842583/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842583</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae171>10.1093/eurheartj/ehae171</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842583</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Giuseppe Mancia</dc:creator>
<dc:creator>Rita Facchetti</dc:creator>
<dc:creator>Guido Grassi</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Risk prediction by ambulatory blood pressure monitoring in non-diabetic and diabetic patients: better than office measurements</dc:title>
<dc:identifier>pmid:38842583</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae171</dc:identifier>
</item>
<item>
<title>Harnessing dendritic cell metabolism for healthy ageing: reducing the risk of cardiovascular disease?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae126. doi: 10.1093/eurheartj/ehae126. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842574</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae126>10.1093/eurheartj/ehae126</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842574</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefanie K Wculek</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Harnessing dendritic cell metabolism for healthy ageing: reducing the risk of cardiovascular disease?</dc:title>
<dc:identifier>pmid:38842574</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae126</dc:identifier>
</item>
<item>
<title>Motherhood penalty and the gender gap in STEM and medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842568/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae262. doi: 10.1093/eurheartj/ehae262. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842568/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842568</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae262>10.1093/eurheartj/ehae262</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842568</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Belinda Di Bartolo</dc:creator>
<dc:creator>Isabel L Torres</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Motherhood penalty and the gender gap in STEM and medicine</dc:title>
<dc:identifier>pmid:38842568</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae262</dc:identifier>
</item>
<item>
<title>Celebrating a journey of 75 years: highlights from the Cardiological Society of India's Annual Conference of 2023</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae259. doi: 10.1093/eurheartj/ehae259. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842553</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae259>10.1093/eurheartj/ehae259</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842553</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Debabrata Roy</dc:creator>
<dc:creator>Dhurjati Prasad Sinha</dc:creator>
<dc:creator>Mrinalkanti Das</dc:creator>
<dc:creator>Pratap Chandra Rath</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Celebrating a journey of 75 years: highlights from the Cardiological Society of India's Annual Conference of 2023</dc:title>
<dc:identifier>pmid:38842553</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae259</dc:identifier>
</item>
<item>
<title>Vago-splenic signal transduction of cardioprotection in humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842545/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In humans, vagal innervation and the spleen as a relay organ are decisive for the cardioprotective signal transduction of RIC and ATS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae250. doi: 10.1093/eurheartj/ehae250. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The spleen serves as an important relay organ that releases cardioprotective factor(s) upon vagal activation during remote ischaemic conditioning (RIC) in rats and pigs. The translation of these findings to humans was attempted.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Remote ischaemic conditioning or electrical auricular tragus stimulation (ATS) were performed in 10 healthy young volunteers, 10 volunteers with splenectomy, and 20 matched controls. Venous blood samples were taken before and after RIC/ATS or placebo, and a plasma dialysate was infused into isolated perfused rat hearts subjected to global ischaemia/reperfusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Neither left nor right RIC or ATS altered heart rate and heart rate variability in the study cohorts. With the plasma dialysate prepared before RIC or ATS, respectively, infarct size (% ventricular mass) in the recipient rat heart was 36 ± 6% (left RIC), 34 ± 3% (right RIC) or 31 ± 5% (left ATS), 35 ± 5% (right ATS), and decreased with the plasma dialysate from healthy volunteers after RIC or ATS to 20 ± 4% (left RIC), 23 ± 6% (right RIC) or to 19 ± 4% (left ATS), 26 ± 9% (right ATS); infarct size was still reduced with plasma dialysate 4 days after ATS and 9 days after RIC. In a subgroup of six healthy volunteers, such infarct size reduction was abrogated by intravenous atropine. Infarct size reduction by RIC or ATS was also abrogated in 10 volunteers with splenectomy, but not in their 20 matched controls.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In humans, vagal innervation and the spleen as a relay organ are decisive for the cardioprotective signal transduction of RIC and ATS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842545/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842545</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae250>10.1093/eurheartj/ehae250</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842545</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Helmut Raphael Lieder</dc:creator>
<dc:creator>Umut Paket</dc:creator>
<dc:creator>Andreas Skyschally</dc:creator>
<dc:creator>Andreas D Rink</dc:creator>
<dc:creator>Theodor Baars</dc:creator>
<dc:creator>Markus Neuhäuser</dc:creator>
<dc:creator>Petra Kleinbongard</dc:creator>
<dc:creator>Gerd Heusch</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Vago-splenic signal transduction of cardioprotection in humans</dc:title>
<dc:identifier>pmid:38842545</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae250</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Irene Lang</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842542/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae280. doi: 10.1093/eurheartj/ehae280. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842542/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842542</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae280>10.1093/eurheartj/ehae280</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842542</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Irene Lang</dc:title>
<dc:identifier>pmid:38842542</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae280</dc:identifier>
</item>
<item>
<title>In memoriam to Professor Jean-Philippe Collet</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842539/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae071. doi: 10.1093/eurheartj/ehae071. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842539/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842539</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae071>10.1093/eurheartj/ehae071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842539</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:creator>Christophe Leclercq</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Franz Weidinger</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>In memoriam to Professor Jean-Philippe Collet</dc:title>
<dc:identifier>pmid:38842539</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae071</dc:identifier>
</item>
<item>
<title>Point-of-care high-sensitivity cardiac troponin in suspected acute myocardial infarction assessed at baseline and 2 h</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842324/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: A 2-h algorithm using a POC hs-cTnI concentration enables safe and efficient risk assessment of patients with suspected AMI. The short turnaround time of POC testing may support significant efficiencies in the management of the large proportion of emergency patients with suspected AMI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae343. doi: 10.1093/eurheartj/ehae343. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Strategies to assess patients with suspected acute myocardial infarction (AMI) using a point-of-care (POC) high-sensitivity cardiac troponin I (hs-cTnI) assay may expedite emergency care. A 2-h POC hs-cTnI strategy for emergency patients with suspected AMI was derived and validated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In two international, multi-centre, prospective, observational studies of adult emergency patients (1486 derivation cohort and 1796 validation cohort) with suspected AMI, hs-cTnI (Siemens Atellica® VTLi) was measured at admission and 2 h later. Adjudicated final diagnoses utilized the hs-cTn assay in clinical use. A risk stratification algorithm was derived and validated. The primary diagnostic outcome was index AMI (Types 1 and 2). The primary safety outcome was 30-day major adverse cardiac events incorporating AMI and cardiac death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 81 (5.5%) and 88 (4.9%) patients in the derivation and validation cohorts, respectively, had AMI. The 2-h algorithm defined 66.1% as low risk with a sensitivity of 98.8% [95% confidence interval (CI) 89.3%-99.9%] and a negative predictive value of 99.9 (95% CI 99.2%-100%) for index AMI in the derivation cohort. In the validation cohort, 53.3% were low risk with a sensitivity of 98.9% (95% CI 92.4%-99.8%) and a negative predictive value of 99.9% (95% CI 99.3%-100%) for index AMI. The high-risk metrics identified 5.4% of patients with a specificity of 98.5% (95% CI 96.6%-99.4%) and a positive predictive value of 74.5% (95% CI 62.7%-83.6%) for index AMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A 2-h algorithm using a POC hs-cTnI concentration enables safe and efficient risk assessment of patients with suspected AMI. The short turnaround time of POC testing may support significant efficiencies in the management of the large proportion of emergency patients with suspected AMI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842324/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842324</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae343>10.1093/eurheartj/ehae343</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842324</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Louise Cullen</dc:creator>
<dc:creator>Jaimi Greenslade</dc:creator>
<dc:creator>William Parsonage</dc:creator>
<dc:creator>Laura Stephensen</dc:creator>
<dc:creator>Stephen W Smith</dc:creator>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Isuru Ranasinghe</dc:creator>
<dc:creator>Niranjan Gaikwad</dc:creator>
<dc:creator>Maryam Khorramshahi Bayat</dc:creator>
<dc:creator>Ehsan Mahmoodi</dc:creator>
<dc:creator>Karen Schulz</dc:creator>
<dc:creator>Martin Than</dc:creator>
<dc:creator>Fred S Apple</dc:creator>
<dc:creator>SAMIE and SEIGE investigators</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Point-of-care high-sensitivity cardiac troponin in suspected acute myocardial infarction assessed at baseline and 2 h</dc:title>
<dc:identifier>pmid:38842324</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae343</dc:identifier>
</item>
<item>
<title>Xylitol: bitter cardiovascular data for a successful sweetener</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842099/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae252. doi: 10.1093/eurheartj/ehae252. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842099/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842099</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae252>10.1093/eurheartj/ehae252</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842099</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Juerg H Beer</dc:creator>
<dc:creator>Meret Allemann</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Xylitol: bitter cardiovascular data for a successful sweetener</dc:title>
<dc:identifier>pmid:38842099</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae252</dc:identifier>
</item>
<item>
<title>Xylitol is prothrombotic and associated with cardiovascular risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38842092/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Xylitol is associated with incident MACE risk. Moreover, xylitol both enhanced platelet reactivity and thrombosis potential in vivo. Further studies examining the cardiovascular safety of xylitol are warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae244. doi: 10.1093/eurheartj/ehae244. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The pathways and metabolites that contribute to residual cardiovascular disease risks are unclear. Low-calorie sweeteners are widely used sugar substitutes in processed foods with presumed health benefits. Many low-calorie sweeteners are sugar alcohols that also are produced endogenously, albeit at levels over 1000-fold lower than observed following consumption as a sugar substitute.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Untargeted metabolomics studies were performed on overnight fasting plasma samples in a discovery cohort (n = 1157) of sequential stable subjects undergoing elective diagnostic cardiac evaluations; subsequent stable isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) analyses were performed on an independent, non-overlapping validation cohort (n = 2149). Complementary isolated human platelet, platelet-rich plasma, whole blood, and animal model studies examined the effect of xylitol on platelet responsiveness and thrombus formation in vivo. Finally, an intervention study was performed to assess the effects of xylitol consumption on platelet function in healthy volunteers (n = 10).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In initial untargeted metabolomics studies (discovery cohort), circulating levels of a polyol tentatively assigned as xylitol were associated with incident (3-year) major adverse cardiovascular event (MACE) risk. Subsequent stable isotope dilution LC-MS/MS analyses (validation cohort) specific for xylitol (and not its structural isomers) confirmed its association with incident MACE risk [third vs. first tertile adjusted hazard ratio (95% confidence interval), 1.57 (1.12-2.21), P &lt; .01]. Complementary mechanistic studies showed xylitol-enhanced multiple indices of platelet reactivity and in vivo thrombosis formation at levels observed in fasting plasma. In interventional studies, consumption of a xylitol-sweetened drink markedly raised plasma levels and enhanced multiple functional measures of platelet responsiveness in all subjects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Xylitol is associated with incident MACE risk. Moreover, xylitol both enhanced platelet reactivity and thrombosis potential in vivo. Further studies examining the cardiovascular safety of xylitol are warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38842092/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38842092</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae244>10.1093/eurheartj/ehae244</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38842092</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Witkowski</dc:creator>
<dc:creator>Ina Nemet</dc:creator>
<dc:creator>Xinmin S Li</dc:creator>
<dc:creator>Jennifer Wilcox</dc:creator>
<dc:creator>Marc Ferrell</dc:creator>
<dc:creator>Hassan Alamri</dc:creator>
<dc:creator>Nilaksh Gupta</dc:creator>
<dc:creator>Zeneng Wang</dc:creator>
<dc:creator>Wai Hong Wilson Tang</dc:creator>
<dc:creator>Stanley L Hazen</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Xylitol is prothrombotic and associated with cardiovascular risk</dc:title>
<dc:identifier>pmid:38842092</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae244</dc:identifier>
</item>
<item>
<title>Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38841854/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with heart failure with preserved ejection fraction in PARAGON-HF had relatively low baseline MMSE scores. Cognitive change, measured by MMSE, did not differ between treatment with sacubitril/valsartan and treatment with valsartan in patients with heart failure with preserved ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 6. doi: 10.1161/CIRCULATIONAHA.124.068774. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked to Alzheimer-type dementia. To address this, we examined the effect of sacubitril/valsartan compared with valsartan on cognitive function in patients with heart failure with preserved ejection fraction in a prespecified substudy of PARAGON-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In PARAGON-HF, serial assessment of cognitive function was conducted in a subset of patients with the Mini-Mental State Examination (MMSE; score range, 0-30, with lower scores reflecting worse cognitive function). The prespecified primary analysis of this substudy was the change from baseline in MMSE score at 96 weeks. Other post hoc analyses included cognitive decline (fall in MMSEs score of ≥3 points), cognitive impairment (MMSE score &lt;24), or the occurrence of dementia-related adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 2895 patients included in the MMSE substudy with baseline MMSE score measured, 1453 patients were assigned to sacubitril/valsartan and 1442 to valsartan. Their mean age was 73 years, and the median follow-up was 32 months. The mean±SD MMSE score at randomization was 27.4±3.0 in the sacubitril/valsartan group, with 10% having an MMSE score &lt;24; the corresponding numbers were nearly identical in the valsartan group. The mean change from baseline to 96 weeks in the sacubitril/valsartan group was -0.05 (SE, 0.07); the corresponding change in the valsartan group was -0.04 (0.07). The mean between-treatment difference at week 96 was -0.01 (95% CI, -0.20 to 0.19; <i>P</i>=0.95). Analyses of a ≥3-point decline in MMSE, decrease to a score &lt;24, dementia-related adverse events, and combinations of these showed no difference between sacubitril/valsartan and valsartan. No difference was found in the subgroup of patients tested for apolipoprotein E ε4 allele genotype.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with heart failure with preserved ejection fraction in PARAGON-HF had relatively low baseline MMSE scores. Cognitive change, measured by MMSE, did not differ between treatment with sacubitril/valsartan and treatment with valsartan in patients with heart failure with preserved ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38841854/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38841854</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068774>10.1161/CIRCULATIONAHA.124.068774</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38841854</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Pooja Dewan</dc:creator>
<dc:creator>Li Shen</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Inder S Anand</dc:creator>
<dc:creator>Alvin Chandra</dc:creator>
<dc:creator>Lu-May Chiang</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Jianjian Gong</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Martin P Lefkowitz</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Felipe Martinez</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Margaret M Redfield</dc:creator>
<dc:creator>Jean L Rouleau</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF</dc:title>
<dc:identifier>pmid:38841854</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068774</dc:identifier>
</item>
<item>
<title>LncRNA DCRT Protects Against Dilated Cardiomyopathy by Preventing NDUFS2 Alternative Splicing by Binding to PTBP1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38841852/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study revealed that the loss of DCRT contributed to PTBP1-mediated exon skipping of NDUFS2, thereby inducing cardiac mitochondrial dysfunction during dilated cardiomyopathy development, which could be partially treated with coenzyme Q10 supplementation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 6. doi: 10.1161/CIRCULATIONAHA.123.067861. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Dilated cardiomyopathy is characterized by left ventricular dilation and continuous systolic dysfunction. Mitochondrial impairment is critical in dilated cardiomyopathy; however, the underlying mechanisms remain unclear. Here, we explored the cardioprotective role of a heart-enriched long noncoding RNA, the dilated cardiomyopathy repressive transcript (DCRT), in maintaining mitochondrial function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The DCRT knockout (DCRT<sup>-/-</sup>) mice and DCRT knockout cells were developed using CRISPR-Cas9 technology. Cardiac-specific DCRT transgenic mice were generated using α-myosin heavy chain promoter. Chromatin coimmunoprecipitation, RNA immunoprecipitation, Western blot, and isoform sequencing were performed to investigate the underlying mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that the long noncoding RNA DCRT was highly enriched in the normal heart tissues and that its expression was significantly downregulated in the myocardium of patients with dilated cardiomyopathy. DCRT<sup>-/-</sup> mice spontaneously developed cardiac dysfunction and enlargement with mitochondrial impairment. DCRT transgene or overexpression with the recombinant adeno-associated virus system in mice attenuated cardiac dysfunction induced by transverse aortic constriction treatment. Mechanistically, DCRT inhibited the third exon skipping of NDUFS2 (NADH dehydrogenase ubiquinone iron-sulfur protein 2) by directly binding to PTBP1 (polypyrimidine tract binding protein 1) in the nucleus of cardiomyocytes. Skipping of the third exon of NDUFS2 induced mitochondrial dysfunction by competitively inhibiting mitochondrial complex I activity and binding to PRDX5 (peroxiredoxin 5) and suppressing its antioxidant activity. Furthermore, coenzyme Q10 partially alleviated mitochondrial dysfunction in cardiomyocytes caused by DCRT reduction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study revealed that the loss of DCRT contributed to PTBP1-mediated exon skipping of NDUFS2, thereby inducing cardiac mitochondrial dysfunction during dilated cardiomyopathy development, which could be partially treated with coenzyme Q10 supplementation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38841852/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38841852</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067861>10.1161/CIRCULATIONAHA.123.067861</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38841852</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Hengzhi Du</dc:creator>
<dc:creator>Yanru Zhao</dc:creator>
<dc:creator>Jianpei Wen</dc:creator>
<dc:creator>Beibei Dai</dc:creator>
<dc:creator>Guo Hu</dc:creator>
<dc:creator>Yufei Zhou</dc:creator>
<dc:creator>Zhongwei Yin</dc:creator>
<dc:creator>Nan Ding</dc:creator>
<dc:creator>Huaping Li</dc:creator>
<dc:creator>Jiahui Fan</dc:creator>
<dc:creator>Xiang Nie</dc:creator>
<dc:creator>Feng Wang</dc:creator>
<dc:creator>Qian Liu</dc:creator>
<dc:creator>Zheng Wen</dc:creator>
<dc:creator>Gang Xu</dc:creator>
<dc:creator>Dao Wen Wang</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>LncRNA DCRT Protects Against Dilated Cardiomyopathy by Preventing NDUFS2 Alternative Splicing by Binding to PTBP1</dc:title>
<dc:identifier>pmid:38841852</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067861</dc:identifier>
</item>
<item>
<title>Genome-Wide Methylation Analysis Reveals a &lt;em>;KCNK3&lt;/em>;-Prominent Causal Cascade on Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38841840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our research reveals new insights into the complex interplay between genetic variations and DNA methylation in hypertension. We underscore hypomethylation's potential in hypertension onset and identify rs1275988 as a causal variant in vascular remodeling. This work advances our understanding of hypertension's molecular mechanisms and encourages personalized health care strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 6. doi: 10.1161/CIRCRESAHA.124.324455. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite advances in understanding hypertension's genetic structure, how noncoding genetic variants influence it remains unclear. Studying their interaction with DNA methylation is crucial to deciphering this complex disease's genetic mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We investigated the genetic and epigenetic interplay in hypertension using whole-genome bisulfite sequencing. Methylation profiling in 918 males revealed allele-specific methylation and methylation quantitative trait loci. We engineered rs1275988<sup>T/C</sup> mutant mice using CRISPR/Cas9, bred them for homozygosity, and subjected them to a high-salt diet. Telemetry captured their cardiovascular metrics. Protein-DNA interactions were elucidated using DNA pull-downs, mass spectrometry, and Western blots. A wire myograph assessed vascular function, and analysis of the <i>Kcnk3</i> gene methylation highlighted the mutation's role in hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We discovered that DNA methylation-associated genetic effects, especially in non-CpG island and noncoding distal regulatory regions, significantly contribute to hypertension predisposition. We identified distinct methylation quantitative trait locus patterns in the hypertensive population and observed that the onset of hypertension is influenced by the transmission of genetic effects through the demethylation process. By evidence-driven prioritization and in vivo experiments, we unearthed rs1275988 in a cell type-specific enhancer as a notable hypertension causal variant, intensifying hypertension through the modulation of local DNA methylation and consequential alterations in <i>Kcnk3</i> gene expression and vascular remodeling. When exposed to a high-salt diet, mice with the rs1275988<sup>C/C</sup> genotype exhibited exacerbated hypertension and significant vascular remodeling, underscored by increased aortic wall thickness. The C allele of rs1275988 was associated with elevated DNA methylation levels, driving down the expression of the <i>Kcnk3</i> gene by attenuating Nr2f2 binding at the enhancer locus.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our research reveals new insights into the complex interplay between genetic variations and DNA methylation in hypertension. We underscore hypomethylation's potential in hypertension onset and identify rs1275988 as a causal variant in vascular remodeling. This work advances our understanding of hypertension's molecular mechanisms and encourages personalized health care strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38841840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38841840</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324455>10.1161/CIRCRESAHA.124.324455</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38841840</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dandan Huang</dc:creator>
<dc:creator>Wenlong Shang</dc:creator>
<dc:creator>Mengtong Xu</dc:creator>
<dc:creator>Qiangyou Wan</dc:creator>
<dc:creator>Jin Zhang</dc:creator>
<dc:creator>Xiaofeng Tang</dc:creator>
<dc:creator>Yujun Shen</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:creator>Ying Yu</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Genome-Wide Methylation Analysis Reveals a &lt;em>;KCNK3&lt;/em>;-Prominent Causal Cascade on Hypertension</dc:title>
<dc:identifier>pmid:38841840</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324455</dc:identifier>
</item>
<item>
<title>Insights into endothelial metabolic heterogeneity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38839882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 5. doi: 10.1038/s41569-024-01049-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38839882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38839882</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01049-3>10.1038/s41569-024-01049-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38839882</guid>
<pubDate>Wed, 05 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Corey McAleese</dc:creator>
<dc:date>2024-06-05</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Insights into endothelial metabolic heterogeneity</dc:title>
<dc:identifier>pmid:38839882</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01049-3</dc:identifier>
</item>
<item>
<title>Phase separation of protein kinase A: a new paradigm in cardiac regulation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38839881/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 5. doi: 10.1038/s41569-024-01048-4. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38839881/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38839881</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01048-4>10.1038/s41569-024-01048-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38839881</guid>
<pubDate>Wed, 05 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Milda Folkmanaite</dc:creator>
<dc:creator>Manuela Zaccolo</dc:creator>
<dc:date>2024-06-05</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Phase separation of protein kinase A: a new paradigm in cardiac regulation?</dc:title>
<dc:identifier>pmid:38839881</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01048-4</dc:identifier>
</item>
<item>
<title>Characterization of the F8 gene: a silver lining in a dark cloud</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38839880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 5. doi: 10.1038/s41569-024-01050-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38839880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38839880</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01050-w>10.1038/s41569-024-01050-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38839880</guid>
<pubDate>Wed, 05 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Daisy Jones</dc:creator>
<dc:date>2024-06-05</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Characterization of the F8 gene: a silver lining in a dark cloud</dc:title>
<dc:identifier>pmid:38839880</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01050-w</dc:identifier>
</item>
<item>
<title>Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38839268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>During the past 30 years, several developments have occurred in the antiplatelet field, including the role of aspirin in primary prevention of atherosclerotic cardiovascular disease. There have been several attempts to develop antiplatelet drugs more effective and safer than aspirin and a shift in emphasis from efficacy to safety, advocating aspirin-free antiplatelet regimens after percutaneous coronary intervention. Evidence supporting a chemopreventive effect of low-dose aspirin against...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 6:ehae324. doi: 10.1093/eurheartj/ehae324. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During the past 30 years, several developments have occurred in the antiplatelet field, including the role of aspirin in primary prevention of atherosclerotic cardiovascular disease. There have been several attempts to develop antiplatelet drugs more effective and safer than aspirin and a shift in emphasis from efficacy to safety, advocating aspirin-free antiplatelet regimens after percutaneous coronary intervention. Evidence supporting a chemopreventive effect of low-dose aspirin against colorectal (and other digestive tract) cancer has also strengthened. The aim of this article is to revisit the role of aspirin in the prevention of atherothrombosis across the cardiovascular risk continuum, in view of developments in the antiplatelet field. The review will offer a clinical perspective on aspirin's mechanism of action, pharmacokinetics, and pharmacodynamics. This will be followed by a detailed discussion of its clinical efficacy and safety.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38839268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38839268</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae324>10.1093/eurheartj/ehae324</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38839268</guid>
<pubDate>Wed, 05 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-06-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease</dc:title>
<dc:identifier>pmid:38839268</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae324</dc:identifier>
</item>
<item>
<title>Remote Monitoring in Heart Failure: Inclusion of Different Studies in the Same Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38839208/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 11;83(23):e231. doi: 10.1016/j.jacc.2024.02.058.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38839208/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38839208</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.058>10.1016/j.jacc.2024.02.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38839208</guid>
<pubDate>Wed, 05 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea Messori</dc:creator>
<dc:creator>Maria Rita Romeo</dc:creator>
<dc:creator>Sabrina Trippoli</dc:creator>
<dc:date>2024-06-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Remote Monitoring in Heart Failure: Inclusion of Different Studies in the Same Meta-Analysis</dc:title>
<dc:identifier>pmid:38839208</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.058</dc:identifier>
</item>
<item>
<title>Reply: Nitrates and Phosphodiesterase-5 Inhibitors: Something's Gotta Give or Maybe Not</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38839207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 11;83(23):e229. doi: 10.1016/j.jacc.2024.04.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38839207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38839207</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.009>10.1016/j.jacc.2024.04.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38839207</guid>
<pubDate>Wed, 05 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ylva Trolle Lagerros</dc:creator>
<dc:creator>Daniel Peter Andersson</dc:creator>
<dc:date>2024-06-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Nitrates and Phosphodiesterase-5 Inhibitors: Something's Gotta Give or Maybe Not</dc:title>
<dc:identifier>pmid:38839207</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.009</dc:identifier>
</item>
<item>
<title>Nitrates and Phosphodiesterase-5 Inhibitors: Something's Gotta Give or Maybe Not?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38839206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 11;83(23):e227-e228. doi: 10.1016/j.jacc.2024.03.422.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38839206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38839206</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.422>10.1016/j.jacc.2024.03.422</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38839206</guid>
<pubDate>Wed, 05 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dimitrios Terentes-Printzios</dc:creator>
<dc:creator>Stergios Soulaidopoulos</dc:creator>
<dc:creator>Nikolaos Ioakeimidis</dc:creator>
<dc:creator>Konstantinos Tsioufis</dc:creator>
<dc:creator>Charalambos Vlachopoulos</dc:creator>
<dc:date>2024-06-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Nitrates and Phosphodiesterase-5 Inhibitors: Something's Gotta Give or Maybe Not?</dc:title>
<dc:identifier>pmid:38839206</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.422</dc:identifier>
</item>
<item>
<title>Water, Soil, Noise, and Light Pollution: JACC Focus Seminar, Part 2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38839205/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240606180819&amp;v=2.18.0.post9+e462414
      <description>Various forms of pollution carry a substantial burden with respect to increasing the risk of causing and exacerbating noncommunicable diseases, especially cardiovascular disease. The first part of this 2-part series on pollution and cardiovascular disease provided an overview of the impact of global warming and air pollution. This second paper provides an overview of the impact of water, soil, noise, and light pollution on the cardiovascular system. This review discusses the biological...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 11;83(23):2308-2323. doi: 10.1016/j.jacc.2024.03.421.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Various forms of pollution carry a substantial burden with respect to increasing the risk of causing and exacerbating noncommunicable diseases, especially cardiovascular disease. The first part of this 2-part series on pollution and cardiovascular disease provided an overview of the impact of global warming and air pollution. This second paper provides an overview of the impact of water, soil, noise, and light pollution on the cardiovascular system. This review discusses the biological mechanisms underlying these effects and potential environmental biometrics of exposure. What is clear from both these pollution papers is that significant efforts and redoubled urgency are needed to reduce the sources of pollution in our environment, to incorporate environmental risk factors into medical education, to provide resources for research, and, ultimately, to protect those who are particularly vulnerable and susceptible.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38839205/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240606180819&v=2.18.0.post9+e462414">38839205</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.421>10.1016/j.jacc.2024.03.421</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38839205</guid>
<pubDate>Wed, 05 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Mark R Miller</dc:creator>
<dc:creator>Philip J Landrigan</dc:creator>
<dc:creator>Manish Arora</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Thomas Münzel</dc:creator>
<dc:creator>Jason C Kovacic</dc:creator>
<dc:date>2024-06-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Water, Soil, Noise, and Light Pollution: JACC Focus Seminar, Part 2</dc:title>
<dc:identifier>pmid:38839205</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.421</dc:identifier>
</item>





























</channel>
</rss>